XFXiaodan Fu

Xiaodan Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaodan Fu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies

    by Yuanyuan Xu, Qihui Wu, Yuxiu Zhang, Jitong Zhao, Xiaodan Fu, Anqi Li, Yimin Li

    Post-translational modifications (PTMs) of histone H3 at lysine 9 (H3K9) contribute to chromatin homeostasis and transcriptional regulation and have been i

  • Open Access

    Arginine methylation in cancer: mechanisms and therapeutic implications

    by Yuanyuan Xu, Qihui Wu, Yuxiu Zhang, Yijin Gu, Hui Zhu, Xiaodan Fu, Anqi Li, Yimin Li

    Arginine methylation is a critical post-translational modification that modulates protein stability, enzymatic activity, and subcellular localization, thereby shaping cell fate decisions and maintaining cellular homeostasis. As the principal enzymes catalyzing this modification, protein arginine methyltransferases (PRMTs) participate in key biological processes, including transcriptional and post-transcriptional regulation as well as signal transduction. Dysregulated PRMT activity has been increasingly linked to tumor initiation, progression, and therapeutic resistance. This review summarizes PRMT classification, structural and functional characteristics, and upstream regulatory mechanisms, offering a framework for understanding their diverse roles in cancer biology and therapeutic relevance. We further discuss the mechanistic contributions of PRMTs to multiple cancer hallmarks and highlight recent advances in the development of PRMT inhibitors. Finally, we examine current strategies for clinical translation, with particular emphasis on combination approaches involving chemotherapy, targeted therapy, and immunotherapy, thereby offering a foundation for advancing PRMT-targeted precision oncology.


  • Open Access

    Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis

    by Qihui Wu, Xiaoyun He, Jiaxin Liu, Chunlin Ou, Yimin Li, Xiaodan Fu

    Background: High-grade serous ovarian cancer (HGSOC) is a challenging malignancy characterized by complex interactions between tumor cells and the surrounding microenvironment. Understanding the immune landscape of HGSOC, particularly the role of the extracellular matrix (ECM), is crucial for improving prognosis and guiding therapeutic interventions. Methods and results: Using univariate Cox regression analysis, we identified 71 ECM genes associated with prognosis in seven HGSOC populations. The ECMscore signature, consisting of 14 genes, was validated using Cox proportional hazards regression with a lasso penalty. Cox regression analyses demonstrated that ECMscore is an excellent indicator for prognostic classification in prevalent malignancies, including HGSOC. Moreover, patients with higher ECMscores exhibited more active stromal and carcinogenic activation pathways, including apical surface signaling, Notch signaling, apical junctions, Wnt signaling, epithelial-mesenchymal transition, TGF-beta signaling, and angiogenesis. In contrast, patients with relatively low ECMscores showed more active immune-related pathways, such as interferon alpha response, interferon-gamma response, and inflammatory response. The relationship between the ECMscore and genomic anomalies was further examined. Additionally, the correlation between ECMscore and immune microenvironment components and signals in HGSOC was examined in greater detail. Moreover, the expression of MGP, COL8A2, and PAPPA and its correlation with FAP were validated using qRT-PCR on samples from HGSOC. The utility of ECMscore in predicting the prospective clinical success of immunotherapy and its potential in guiding the selection of chemotherapeutic agents were also explored. Similar results were obtained from pan-cancer research. Conclusion: The comprehensive evaluation of the ECM may help identify immune activation and assist patients in HGSOC and even pan-cancer in receiving proper therapy.


  • Open Access

    Analyzing the extracellular matrix-dominated immune landscape of high-grade serous ovarian cancer to determine prognosis and guide therapy

    by Qihui Wu, Xiaoyun He, Jiaxin Liu, Chunlin Ou, Yinmin Li, Xiaodan Fu

    High grade serous ovarian cancer (HGSOC) is associated with a poor prognosis and a high recurrence rate. For high-risk patients, personalized treatment augmentation and clinically relevant molecular prognostic indicators are required. As extracellular matrix (ECM) are very active component of the tumor microenvironment, influencing the behavior and metastatic potential of tumor cells, understanding ECM function may aid in the development of useful diagnostics and innovative medicines for HGSOC. Using univariate Cox regression analysis, we identified 71 ECM genes associated with prognosis in seven HGSOC populations. Cox proportional hazards regression with lasso penalty was utilized to validate the ECMscore signature of 14 genes. Analyses of Cox regression indicate that ECMscore is an excellent indication for prognostic classification in the most prevalent malignancies, including HGSOC. In addition, we found that patients with a higher ECMscore exhibited more active stromal and carcinogenic activation pathways, including apical Surface, Notch signaling, apical Junction, Wnt signaling, epithelial-mesenchymal transition, TGF-ß signaling, and angiogenesis. In contrast, patients with a relatively low ECMscore had more active immune-related pathways, such as interferon alpha response, interferon-gamma response, and inflammatory response. The relationship between the ECMscore and genome anomalies was further examined. In addition, the interaction between ECMscore and immune microenvironment components and signals in HGSOC was examined in greater detail. As one of the hubs, the expression of MGP and its relationship to FBN1 were validated using qRT-PCR on HGSOC samples. The utility of ECMscore in predicting the prospective clinical success of immunotherapy and its capacity to guide the selection of chemotherapeutic medicines were also investigated. Additionally, pan-cancer research showed similar results. In conclusion, a comprehensive evaluation of the ECM may enable the identification of immune activation and help patients in HGSOC and pan-cancer to obtain the proper therapy.

  • Open Access

    A comprehensive analysis focusing on cuproptosis to investigate its clinical and biological relevance in uterine corpus endometrial carcinoma and its potential in indicating prognosis

    by Qihui Wu, Ruotong Tian, Hong Tan, Jiaxin Liu, Chunlin Ou, Yimin Li, Xiaodan Fu

    Cuproptosis, a novel copper-dependent cell death involving mitochondrial respiration, is distinct from other known death mechanisms, which inspires us to study further in uterine corpus endometrial carcinoma (UCEC). Herein, leveraging comprehensive data from TCGA-UCEC, we conducted transcriptional and genetic analyses of 13 recently identified cuproptosis genes. We discovered severe genetic instability of cuproptosis genes, extensive positive correlations among those genes with each other at the mRNA level, and their involvement in oncogenic pathways in UCEC samples. Next, WGCNA was performed to identify a potential module regulating cuproptosis, in which the hub genes, in addition to 13 cuproptosis genes, were drawn to construct a scoring system termed Cu. Score. Furthermore, its clinical and biological relevance and tumor immune landscape, genetic alterations, as well as predicted sensitivity of chemotherapy drugs in different Cu. Score subgroups had been discussed extensively and in detail. Additionally, univariate Cox and LASSO regression were performed to identify 13 cuproptosis-related prognostic genes to establish a prognostic signature, the Risk. Score. Integrating the Risk. Score and clinical parameters, we established a nomogram with excellent performance to predict the 1-/3-/5-year survival probabilities of UCEC patients. To conclude, we conducted a comprehensive analysis encompassing cuproptosis and developed a cuproptosis scoring system and a prognostic prediction model for UCEC, which may offer help with individualized assessment and treatment for UCEC patients from the perspective of a novel death mechanism.


  • Open Access

    Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma

    by Yimin Li, Ruotong Tian, Jiaxin Liu, Juanni Li, Hong Tan, Qihui Wu, Xiaodan Fu

    Limited immunotherapeutic effect in high-grade serous ovarian carcinoma (HGSOC) propels exploration of the mechanics behind this resistance, which may be partly elucidated by investigating characters of cancer-associated fibroblasts (CAFs), a significant population in HGSOC involved in shaping tumor immune microenvironment. Herein, leveraging gene expression data of HGSOC samples from The Cancer Genome Atlas and Gene Expression Omnibus datasets, we suggested that CAFs detrimentally affected the outcomes of HGSOC patients. Subsequently, we performed weighted gene co-expression network analysis (WGCNA) to identify a CAFs-related module and screened out seven hub genes from this module, all of which were positively correlated with the infiltration of immunosuppressive macrophages. As one of the hub genes, the expression of fibrillin 1 (FBN1) and its relevance to CD206 were further verified by immunohistochemistry staining in HGSOC samples. Meanwhile, we extracted genes that correlated well with CAF signatures to construct a CAFscore. The capacity of the CAFscore as an independent prognostic factor was validated by Cox regression analyses, and its relevance to components as well as signals in the tumor immune microenvironment was also investigated. Under the evaluation by the CAFscore, HGSOC patients with relatively high CAFscore had worse outcomes, activated mesenchymal signaling pathways, and immune checkpoint blockade (ICB) resistance signatures, which was consistent with the fact that non-responders in anti-PD-1 treatment cohorts tended to have higher CAFscore. Besides, the possibility of CAFscore to guide the selection of sensitive chemotherapeutic agents was explored. In conclusion, individualized assessment of the CAFscore could uncover the extent of stroma activation and immunosuppression and inform therapeutic strategies to improve the benefit of therapies.


  • Open Access

    A 13-Gene Signature Based on Estrogen Response Pathway for Predicting Survival and Immune Responses of Patients With UCEC

    by Yimin Li, Ruotong Tian, Jiaxin Liu, Chunlin Ou, Qihui Wu, Xiaodan Fu

    Background: Accumulating evidence suggests that anti-estrogens have been effective against multiple gynecological diseases, especially advanced uterine corpus endometrial carcinoma (UCEC), highlighting the contribution of the estrogen response pathway in UCEC progression. This study aims to identify a reliable prognostic signature for potentially aiding in the comprehensive management of UCEC.Methods: Firstly, univariate Cox and LASSO regression were performed to identify a satisfying UCEC prognostic model quantifying patients’ risk, constructed from estrogen-response-related genes and verified to be effective by Kaplan-Meier curves, ROC curves, univariate and multivariate Cox regression. Additionally, a nomogram was constructed integrating the prognostic model and other clinicopathological parameters. Next, UCEC patients from the TCGA dataset were divided into low- and high-risk groups according to the median risk score. To elucidate differences in biological characteristics between the two risk groups, pathway enrichment, immune landscape, genomic alterations, and therapeutic responses were evaluated to satisfy this objective. As for treatment, effective responses to anti-PD-1 therapy in the low-risk patients and sensitivity to six chemotherapy drugs in the high-risk patients were demonstrated.Results: The low-risk group with a relatively favorable prognosis was marked by increased immune cell infiltration, higher expression levels of HLA members and immune checkpoint biomarkers, higher tumor mutation burden, and lower copy number alterations. This UCEC prognostic signature, composed of 13 estrogen-response-related genes, has been identified and verified as effective.Conclusion: Our study provides molecular signatures for further functional and therapeutic investigations of estrogen-response-related genes in UCEC and represents a potential systemic approach to characterize key factors in UCEC pathogenesis and therapeutic responses.